$2.50
0.00% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US92941V1008
Symbol
VYNE
Sector
Industry

VYNE Therapeutics Inc Stock price

$2.50
-0.25 9.09% 1M
+0.70 38.89% 6M
-0.85 25.37% YTD
+0.13 5.49% 1Y
-7.26 74.38% 3Y
-192.62 98.72% 5Y
-2,064.62 99.88% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.05 1.96%
ISIN
US92941V1008
Symbol
VYNE
Sector
Industry

Key metrics

Market capitalization $36.88m
Enterprise Value $-33.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.10
EV/Sales (TTM) EV/Sales -67.82
P/S ratio (TTM) P/S ratio 75.27
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth 39.27%
Revenue (TTM) Revenue $490.00k
EBIT (operating result TTM) EBIT $-37.70m
Free Cash Flow (TTM) Free Cash Flow $-30.11m
Cash position $70.23m
EPS (TTM) EPS $-0.85
P/E forward negative
P/S forward 69.15
EV/Sales forward negative
Short interest 0.34%
Show more

Is VYNE Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

VYNE Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a VYNE Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a VYNE Therapeutics Inc forecast:

Buy
100%

Financial data from VYNE Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.49 0.49
40% 40%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
5% 5%
2,839%
- Research and Development Expense 24 24
38% 38%
4,957%
-38 -38
23% 23%
-7,694%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -38 -38
24% 24%
-7,694%
Net Profit -34 -34
6% 6%
-6,935%

In millions USD.

Don't miss a Thing! We will send you all news about VYNE Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VYNE Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE's management will participate in two investor conferences in March.
Neutral
GlobeNewsWire
9 days ago
BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to...
Neutral
GlobeNewsWire
about 2 months ago
BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of ...
More VYNE Therapeutics Inc News

Company Profile

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

Head office United States
CEO David Domzalski
Employees 10
Founded 2011
Website www.vynetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today